Company / Net Debt per Share
Halozyme Net Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
$16.31
FY2025
5-year range
$4.95 / $16.31
FY2021-FY2025
Trend
+48.8%
vs FY2024
Sector context
#12 of 82
Health Care
What the data says
Halozyme's net debt per share of $16.31 is higher than 85% of companies in the Health Care sector (FY2025). Net Debt per Share has increased for 5 consecutive years, from $-1.08 in FY2020 to $16.31 in FY2025.
Based on SEC 10-K filings.
16.31 in FY2025 with a 3-year CAGR of +20.8%. Top quartile in the Health Care sector.
Increased from $10.22 to $16.31 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- +20.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
+1343.4% above sector average
Key checks
Key Insights
- Halozyme's net debt per share has grown for 5 consecutive years.
- In FY2025, net debt per share increased 48.8% year-over-year.
- Ranks #12 out of 82 companies in the Health Care sector.
- Lowest net debt per share in the period was in FY2020.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.31 | +48.8% |
| FY2024 | $10.96 | +7.3% |
| FY2023 | $10.22 | +10.5% |
| FY2022 | $9.25 | +86.8% |
| FY2021 | $4.95 | +558.3% |
| FY2020 | -$1.08 | -159.5% |
| FY2019 | $1.82 | +1224.6% |
| FY2018 | -$0.16 | +52.0% |
| FY2017 | -$0.34 | -132.6% |
| FY2016 | $1.03 | +21064.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026